Pharmafile Logo

Debra Ainge

Achieving insight

Understanding the needs of people is key to the success of developing a patient-focused intervention. If you don’t do the research to understand the end user, then you are building...

Eli Lilly HQ

Lilly drops Hanmi-partnered arthritis drug

Concludes that its BTK inhibitor is likely to be clinically ineffective

- PMLiVE

Shaky mid-stage data won’t halt Celgene’s plans for Otezla

The US biotech will continue to test the drug in patients with UC and Behçet’s disease

- PMLiVE

Cello Health launches new social media and analytics offering

Cello Health Logic will specialise in healthcare and pharmaceuticals

Shire teams up with Microsoft and EURORDIS for rare disease project

Will work to accelerate the time to diagnosis for children

- PMLiVE

mXm Group bolsters its editorial and account handing teams

New joiners include Chris Watson, Tony Cornell and Sunita Ram

Metrion Biosciences establishes scientific advisory board

The board will provide scientific oversight and strategic advice to Metrion

- PMLiVE

Ten years at the forefront of patient experience

This month marks ten years of Hive, which has prompted us to reflect on how the world has changed over the last decade, and how it is going to change...

- PMLiVE

Big data, privacy and the rise of genomic testing

Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Blue Latitude Health

Deal Watch January 2018

One key question for 2018 is whether the recent US tax changes will have an effect on M&A in our industry - time will tell.  The year opened with a small...

Traditional vs Flipped

Emotional Intelligence and Blended Learning in Healthcare

EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action.

Cuttsy + Cuttsy

- PMLiVE

AbbVie reports more solid data for would-be psoriasis blockbuster

Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links